| ¿µ¹® | thyroid carcinoma | ÇÑ±Û | °©»ó»ù¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | °©»ó»ù¿¡ »ý±ä »óÇǼ¼Æ÷·Î ÀÌ·ç¾îÁø ¾Ç¼ºÁ¾¾ç¹°. º´¸®Á¶Á÷ÇÐÀûÀÎ ÇüÅ¿¡ µû¶ó À¯µÎ»ó, ¼ÒÆ÷»ó, ¿ªÇü¾ÏÁ¾ ¹× ¼öÁú¾ÏÁ¾, ¸²ÇÁÁ¾ µîÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ´Ù¾çÇÑ ¿øÀÎÀÌ ÀÖÀ¸³ª, ÀϺο¡¼´Â ¹æ»ç¼±Æø·Î¿¡ ÀÇÇØ ¹ß»ýÇÑ´Ù. Ä¡·á´Â ¼ö¼ú, ¹æ»ç¼º ¿Á¼Ò, T4 ¾ïÁ¦¿ä¹ý µîÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | risk factor | ÇÑ±Û | À§ÇèÀÎÀÚ |
|---|---|---|---|
| ¼³¸í | ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î äÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ ÀÖ¾î¼ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» ÇÏ¸é¼ ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£3/SvÀÌ´Ù. |
||
| ¿µ¹® | thyroid gland | ÇÑ±Û | °©»ó»ù |
|---|---|---|---|
| ¼³¸í | »ç¶÷ÀÇ ¸ö¿¡¼ °¡Àå Å« ³»ºÐºñ»ùÀ¸·Î ¸ñÀÇ ¾ÕÂÊ, ¾Æ·¡ÂÊ¿¡ À§Ä¡Çϰí ÀÖÀ¸¸ç 2¿±À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. °¢ ¿±Àº ±â°üÀÇ ¾çÂÊ¿¡ ÀÖÀ¸¸ç Á¼Àº Àß·è¿¡ ÀÇÇØ ¾Õ¿¡¼ ¿¬°áµÇ¾î ÀÖ´Ù. °©»ó»ùÈ£¸£¸óÀΠƼ·Ï½Å(thyroxine)À» ºÐºñÇϰí ÀúÀåÇϸç, Çʿ信 µû¶ó ¹æÃâÇÑ´Ù. ¶ÇÇÑ °©»ó»ùÀº Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)µµ ºÐºñÇÑ´Ù. º´ÀûÀÎ »óÅ¿¡¼ Å©±â°¡ ´ë°³ Áõ°¡Çϰí, ÀϺο¡¼´Â µµ¸®¾î À§ÃàµÇ¸ç, ÅëÁõÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. |
||
| ¿µ¹® | thyroid hormone | ÇÑ±Û | °©»ó»ùÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ±¤ÀÇÀÇ °©»ó¼±È£¸£¸óÀº Ƽ·Ï½Å(thyroxine(T4)), »ï¿äµåƼ·Î´Ñ(triiodothyronine (T3)), Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)ÀÇ 3°¡ÁöÁß Çϳª¸¦ ¸»Çϳª ´ë°³ÀÇ °æ¿ì ÇùÀÇÀÇ ¶æÀ¸·Î »ç¿ëµÇ¸ç ÀÌ °æ¿ì Ƽ·Ï½Å°ú »ï¿äµåƼ·Î´ÑÀ» ÁöĪÇÑ´Ù. °©»ó¼± È£¸£¸óÀº °ÅÀÇ ¸ðµç ¸ö¼¼Æ÷¿¡¼ÀÇ ¹ÙÅÁÁú´ë»ç¿¡ °ü¿©ÇÏ¿© ¿¡³ÊÁö»ý¼ºÀ» Áõ°¡½ÃŰ°í ¼ºÀå ¹ßÀ°À» ÃËÁøÇÑ´Ù. À̰ÍÀº ³úÇϼöü¿¡¼ ºÐºñµÇ´Â °©»ó»ù ÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ÇÕ¼º ¹× ºÐºñ°¡ ÃËÁøµÈ´Ù. ¼·ÃëÇÏ¿© ü³»¿¡ µé¾î¿Â ¿ä¿Àµå°¡ ´Éµ¿¿î¹Ý¿¡ ÀÇÇØ °©»ó»ù¼¼Æ÷³»·Î µé¾î°¡ ¼¼Æ÷³»¿¡ ÀÖ´Â ´Ü¹éÁúÀÎ °©»ó»ù ±Û·Îºí¸°°ú °áÇÕÇÏ¿© °©»ó»ùÈ£¸£¸óÀ¸·Î ÇÕ¼ºµÈ´Ù. ¿ä¿Àµå°¡ 3ºÐÀÚ °áÇÕÇÑ °ÍÀ» T3, 4ºÐÀÚ °áÇÕÇÑ °ÍÀ» T4¶ó ºÎ¸§. ºÐºñµÇ´Â °©»ó¼± È£¸£¸óÁß 90%ÀÌ»óÀÌ T4ÀÌ´Ù. Ç÷ÁßÀ¸·Î ºÐºñµÈ °©»ó»ùÈ£¸£¸óÀº Ç÷Áß ´Ü¹éÁú°ú °áÇÕÇϴµ¥ ´ëºÎºÐÀº Ƽ·Ð½Å°áÇÕ±Û·Îºí¸°°ú °áÇÕÇϸç ÀϺδ ¾ËºÎ¹Î°ú °áÇÕÇÑ´Ù. Àü¹ÝÀûÀÎ ´ë»çÀ²À» ÃËÁø½ÃŰ¸ç ¾î¸°ÀÌ¿¡¼´Â ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ƯÈ÷ ¾î¸°ÀÌ¿¡¼ ¸ô´Ü¹éÁú ÇÕ¼ºÀ» ÃËÁøÇÏ¸ç ³úÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ±â´ÉÀ» ÇÔÀ¸·Î½á, ¼±Ãµ¼º °©»ó»ùÀúÇÏÁõ(cretinism)À» Á¶±â ¹ß°ßÇÏ¿© Ä¡·áÇÏÁö ¸øÇϸé Á¤½ÅÁöü°¡ À¯¹ßµÈ´Ù. °©»ó»ù°ú´ÙÁõÀÇ Áõ»óÀº ü³» ´ë»ç°¡ Ç×ÁøµÇ¾î ½Ä¿åÀÌ Áõ°¡Çϳª üÁßÀÌ °¨¼ÒÇÏ°í ½ÉÀå¹Úµ¿¼ö°¡ Áõ°¡ÇÏ°í ´õÀ§¸¦ ÂüÁö ¸øÇϸç, °©»ó»ù±â´ÉÀúÇÏÁõÀÇ Áõ»óÀº À§¿Í ¹Ý´ë·Î ½Ä¿åÀÌ °¨¼ÒÇϰí üÁßÀÌ Áõ°¡ÇÏ¸ç ½ÉÀå¹Úµ¿¼ö°¡ °¨¼ÒÇϰí ÃßÀ§¸¦ ÂüÁö ¸øÇϸç ÇǺο¡ ´Ü¹éÁúÀÌ ÃàÀûµÇ¾î Á¡¾×ºÎÁ¾ÀÌ À¯¹ßµÈ´Ù. |
||
| ¿µ¹® | bronchogenic carcinoma | ÇÑ±Û | ±â°üÁö¿ø¼º ¾ÏÁ¾ |
|---|---|---|---|
| ¼³¸í | ÆóÀÇ ±â°üÁö ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾ç. Æó¾ÏÀÇ Á¾·ù¿¡¼ °¡Àå ÈçÇÑ ÇüÅÂ(90%ÀÌ»ó)ÀÌ´Ù. Çö¹Ì°æÀû ¼Ò°ß¿¡ µû¶ó »ù¾ÏÁ¾, Å«¼¼Æ÷¾ÏÁ¾, ¼Ò¼¼Æ÷(ÀÛÀº¼¼Æ÷) ¾ÏÁ¾ÀÇ 4°¡Áö·Î ³ª´«´Ù. ÀÌÁß¿¡¼ ÆíÆò¼¼Æ÷¾ÏÁ¾ÀÌ °¡Àå ÈçÇÑ ÇüÅÂÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ºñ¼Ò¼¼Æ÷Æó¾Ï(non-small cell lung cancer)¿Í ¼Ò¼¼Æ÷Æó¾Ï(small cell lung cancer)·Î ±¸ºÐÀ» Çϴµ¥, ºñ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì Á¾¾ç¼¼Æ÷ÀÇ ¼ºÀåÀÌ ´À¸®°í ¼ö¼úÀû Á¦°Å°¡ Ä¡·áÀÇ ±âº»ÀÌ µÇ°í ¿¹Èĵµ ÁÁÀº ¹Ý¸é, ¼Ò¼¼Æ÷Æó¾ÏÀÇ °æ¿ì¿¡´Â ¾Ï¼¼Æ÷ÀÇ ¼ºÀåÀÌ ¸Å¿ì ºü¸£°í Ä¡·áµµ ¹æ»ç¼±Ä¡·á¸¦ ±âº»À¸·Î ÇÏ¸ç ¿¹Èĵµ ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡ ºñÇØ¼ ÁÁÁö°¡ ¸øÇÏ´Ù. |
||
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
|---|---|
| CDSRF | chronic disease and sociodemographic risk factors |
| CSPINE | corticosteroid use, seropositive RA, peripheral joint destruction, involvement of cervical nerves, n... |
| AR | absolute risk; accounts receivable; achievement ratio; actinic reticuloid [syndrome]; active resista... |
| CRI | Cardiac Risk Index; catheter-related infection; chronic renal insufficiency; chronic respiratory ins... |
| ATC | Anaplastic thyroid carcinoma |
|---|---|
| DTC | Differentiated Thyroid Carcinoma |
| FMTC | Familial Medullary Thyroid Carcinoma |
| FTC | Follicular thyroid carcinoma |
| MTC | Medullary Thyroid Carcinoma |
| thyroid carcinoma risk factors | <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma (12 Dec 1998) |
|---|
| oesophageal carcinoma risk factors | <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma (12 Dec 1998) |
|---|---|
| glaucoma, risk factors | If you belong to a high-risk group for glaucoma, have your eyes examined through dilated pupils every 2 years by an eye care professional. High-risk groups include everyone with a family history of glaucoma, everyone over the age of 60 and any Black over the age of 40. (Among Blacks, studies show that glaucoma is: 5 times more likely to occur in Blacks than in Whites and about 4 times more likely to cause blindness in Blacks than in Whites). (12 Dec 1998) |
| risk factors | An aspect of personal behaviour or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent. (12 Dec 1998) |
| anaplastic carcinoma of the thyroid | <oncology, tumour> An aggressive form and rare form of thyroid cancer that is one of the most rapidly growing and invasive types of thyroid cancer. It commonly occurs in people over 60 years of age and may cause obstruction of the trachea. The cause is unknown but exposure to radiation may be a factor. Thyroid function tests are usually normal. Hoarse voice, cough and coughing up blood are common symptoms. Examination may reveal nodules in the thyroid gland. Diagnosis is made via biopsy. Treatment is surgical with or without radiation therapy. (27 Sep 1997) |
| giant cell carcinoma of thyroid gland | A rapidly progressive undifferentiated carcinoma observed in the thyroid gland, characterised by numerous, unusually large, anaplastic cells derived from glandular epithelium of the thyroid gland. (05 Mar 2000) |
| thyroid carcinoma | <radiology> Papillary-follicular (75%), well-differentiated, 95% 5-yr survival with treatment, papillary may lead to neck nodes, follicular may lead to lungs, bone (haematogenous), anaplastic (20%), older patients, prognosis poor, medullary (5%), C cells, associated with pheochromocytoma (MEN-2 and MEN-3) see also: hot and cold nodules on radionuclide studies, risk factors (12 Dec 1998) |
| lateral aberrant thyroid carcinoma | <tumour> A cervical nodule of thyroid carcinoma situated outside the thyroid gland, formerly thought to arise from ectopic thyroid tissue but now believed to be metastatic from an occult carcinoma within the gland. (05 Mar 2000) |
| absolute risk | <statistics> The excess risk due to exposure to a specific hazard (disease, injury, etc.) (15 Jan 1998) |
| acceptable risk | <statistics> This relates to the potential for suffering disease or injury that will be tolerated by an individual, group, or society in exchange for the benefits of using a substance or process that will cause such disease or injury. Acceptability of risk depends on scientific data, social, economic, and political factors, and on the perceived benefits arising from a chemical or process that creates the risk in question. (15 Jan 1998) |
| attributable risk | The rate of a disease or other outcome in exposed individuals that can be attributed to the exposure. (05 Mar 2000) |
| cardiac risk | A term to describe overall risk of developing heart disease (blockage of the coronary arteries). Typical risk factors include: diabetes, high blood pressure, prior heart attack, high cholesterol, obesity, smoking and a family history for heart attacks in parents or siblings. (27 Sep 1997) |
| recurrence risk | In medical genetics, the recurrence risk is the chance that a genetic (inherited) disease present in the family will recur in that family and affect another person (or persons). It is the chance of lightning striking twice (or thrice, etc.). (12 Dec 1998) |
| relative risk | <epidemiology> The proportion of diseased people amongst those exposed to the relevant risk factor divided by the proportion of diseased people amongst those not exposed to the risk factor. This should be used in those cohort studies where those with and without disease are followed to observe which individuals become diseased. (05 Dec 1998) |
| risk | The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. (12 Dec 1998) |
| risk assessment | The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|